There was a significant difference in ER, PR, Ki67 status, and molecular subtypes and no significant differences in age, baseline maximum tumor diameter, HER-2 status, clinical T/N stage, menopausal status, histological type, or neoadjuvant treatment protocol between the two groups. Here, PGR is linked to neoplasm.